Current status of biomedical products for gene and cellular therapy of recessive dystrophic epidermolysis bullosa (review, part II)
- 1 July 2025
- journal article
- Published by Media Sphere Publishing Group in Russian Journal of Clinical Dermatology and Venereology
- Vol. 24 (3)
Abstract
Recessive dystrophic epidermolysis bullosa (RDEB) is a rare hereditary disease characterized by a high skin susceptibility, formation of bubbles, erosions, chronic lesions, chronic systemic inflammation. The use of mesenchymal stem/stromal cells (MSCs) isolated from different sources can be considered as one of the RDEB treatment methods. MSCs are an ideal candidate for treating a wide range of serious diseases due to the simplicity of their isolation and reproduction, the ability to differentiate into multiple cell lines, the ability to neovasculogenesis, as well as in consequence of the pronounced paracrine effect through the production of anti-inflammatory, immunomodulating, antiapoptotic, antifibrotic and anabolic factors, that leads to damaged tissues’ recovery. At the same time, MSCs have a low immunogenicity that allows to use allogenic MSCs (without the need for aggressive patient’s conditioning as in the case of allogenic transplantation of bone marrow cells), that is especially relevant due to the RDEB nature associated with systemic inflammation. This therapy can significantly decrease the disease activity and improve the life quality of patients with RDEB by reducing inflammatory processes in the body and relieving persistent and highly disturbing symptoms — itching and pain. The article summarizes the mechanisms by which MSCs contribute to healing skin lesions, systemic anti-inflammatory effect in the treatment of patients with RDEB. The results of pre-clinical and clinical studies have been also discussed.Keywords
This publication has 59 references indexed in Scilit:
- A Brief Overview of Global Trends in MSC-Based Cell TherapyStem Cell Reviews and Reports, 2022
- Newly Defined ATP-Binding Cassette Subfamily B Member 5 Positive Dermal Mesenchymal Stem Cells Promote Healing of Chronic Iron-Overload Wounds via Secretion of Interleukin-1 Receptor AntagonistStem Cells, 2019
- The mesenchymal stem cell secretome: A new paradigm towards cell-free therapeutic mode in regenerative medicineCytokine & Growth Factor Reviews, 2019
- Dual mechanism of type VII collagen transfer by bone marrow mesenchymal stem cell extracellular vesicles to recessive dystrophic epidermolysis bullosa fibroblastsBiochimie, 2018
- Suppression of Neutrophil-Mediated Tissue Damage—A Novel Skill of Mesenchymal Stem CellsStem Cells, 2016
- ABCB5 Identifies Immunoregulatory Dermal CellsCell Reports, 2015
- The Gap Between the Physiological and Therapeutic Roles of Mesenchymal Stem CellsMedicinal Research Reviews, 2014
- Crosstalk Between Mesenchymal Stem Cells and Endothelial Cells Leads to Downregulation of Cytokine-Induced Leukocyte RecruitmentStem Cells, 2013
- Human Stromal (Mesenchymal) Stem Cells from Bone Marrow, Adipose Tissue and Skin Exhibit Differences in Molecular Phenotype and Differentiation PotentialStem Cell Reviews and Reports, 2012
- Isolation and characterization of mesenchymal stem cells from human umbilical cord blood: Reevaluation of critical factors for successful isolation and high ability to proliferate and differentiate to chondrocytes as compared to mesenchymal stem cells from bone marrow and adipose tissueJournal of Cellular Biochemistry, 2011